Genmab A/S Target of Unusually Large Options Trading (NASDAQ:GMAB)

Genmab A/S Sponsored ADR (NASDAQ:GMAB) saw unusually large options trading activity on Tuesday. Stock traders purchased 4,639 call options on the company. This is an increase of 332% compared to the average daily volume of 1,074 call options.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price objective on shares of Genmab A/S in a research report on Tuesday. Weiss Ratings lowered Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Wolfe Research started coverage on Genmab A/S in a research note on Friday, March 27th. They issued an “outperform” rating and a $32.00 target price for the company. Wells Fargo & Company began coverage on Genmab A/S in a research report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price target on the stock. Finally, Guggenheim reduced their price target on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $37.93.

Institutional Trading of Genmab A/S

Institutional investors have recently bought and sold shares of the company. Orbis Allan Gray Ltd raised its holdings in Genmab A/S by 30.2% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock worth $444,089,000 after buying an additional 3,340,456 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Genmab A/S by 2.7% during the third quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company’s stock valued at $335,957,000 after buying an additional 291,538 shares during the last quarter. Paradigm Biocapital Advisors LP grew its holdings in shares of Genmab A/S by 84.4% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company’s stock valued at $216,827,000 after buying an additional 3,222,983 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Genmab A/S by 36.6% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after acquiring an additional 1,334,919 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Genmab A/S by 26.4% during the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after acquiring an additional 921,700 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Up 1.7%

Genmab A/S stock traded up $0.43 during mid-day trading on Tuesday, hitting $26.04. The company had a trading volume of 499,780 shares, compared to its average volume of 1,790,847. Genmab A/S has a 12 month low of $20.23 and a 12 month high of $35.43. The company has a market capitalization of $16.23 billion, a PE ratio of 19.71, a price-to-earnings-growth ratio of 1.50 and a beta of 0.85. The stock’s 50 day moving average price is $26.44 and its two-hundred day moving average price is $28.95. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.